CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 154 enrolled
Drug / intervention
IVM w/ ALB +2 moredrug
Likely dose
IVM w/ ALB 150 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04188301
NCT04188301Phase 2Completed
CompareCT.gov

Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis

Washington University School of Medicine·interventional·Posted Dec 5, 2019·Updated Jun 4, 2024

In Brief

A Phase 2 clinical trial evaluating IVM w/ ALB, Single dose of IDA, and 1 other intervention for Onchocerciasis. Completed, enrolled 154 participants across 1 site.

Detailed Summary

This DOLF study will investigate the safety and effectiveness of IDA treatment in persons with onchocerciasis when it is administered after pre-treatment with ivermectin to clear or greatly reduce microfilariae from the skin and eyes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOnchocerciasis
CountriesGhana
CollaboratorsCase Western Reserve University, University of Health and Allied Sciences

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 5, 2019
Enrollment StartDec 6, 2019
Primary CompletionMar 14, 2022
Study CompletionJun 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.6 years ago

Interventions

IVM w/ ALBdrug

Participants will be given a single dose of oral IVM (150 µg/kg) plus ALB (400 mg) (IVM/ALB)

Single dose of IDAdrug

Participants will be given a single dose of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)

Three daily doses of IDAdrug

Participants will be given one daily dose for 3 days of oral IVM (150 µg/kg), DEC (6 mg/kg) and ALB (400 mg)